Evidence map›Paper›PMID 38638373›Full record

ArticleJournal of clinical and translational hepatology2024

A Revised Classification of Primary Iron Overload Syndromes.

Yasuaki Tatsumi, Motoyoshi Yano, Shinya Wakusawa, Hiroaki Miyajima, Tetsuya Ishikawa, Shinsaku Imashuku, Atsuko Takano, Wataru Nihei, Ayako Kato, Koichi Kato and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical and translational hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Yasuaki TatsumiDepartment of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Japan.
Motoyoshi YanoDepartment of Gastroenterology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
Shinya WakusawaDepartment of Medical Technology, Shubun University, Ichinomiya, Japan.
Hiroaki MiyajimaDepartment of Medicine and Neurology, Tenryu Kohseikai Clinic, Hamamatsu, Japan.
Tetsuya IshikawaDepartment of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shinsaku ImashukuDepartment of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji, Japan.
Atsuko TakanoDepartment of Medicine, Saiseikai Takaoka Hospital, Takaoka, Japan.
Wataru NiheiDepartment of Medicine, Aichi-Gakuin University School of Pharmacy, Nagoya, Japan.
Ayako KatoDepartment of Medicine, Aichi-Gakuin University School of Pharmacy, Nagoya, Japan.
Koichi KatoDepartment of Medicine, Aichi-Gakuin University School of Pharmacy, Nagoya, Japan.
Hisao HayashiDepartment of Medicine, Aichi-Gakuin University School of Pharmacy, Nagoya, Japan.ORCID https://orcid.org/0000-0002-4934-2656
Kentaro YoshiokaDepartment of Gastroenterology, FNPS Meijo Hospital, Nagoya, Japan.
Kazuhiko HayashiDepartment of Gastroenterology, FNPS Meijo Hospital, Nagoya, Japan.
Aichi Gakuin University · JPMeijo Hospital · JPHamamatsu Medical Center · JPNagoya University · JPSaiseikai Takaoka Hospital · JPShubun University · JPSuita Tokushukai Hospital · JPToho University · JPYokkaichi Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The clinical introduction of hepcidin25 (Hep25) has led to a more detailed understanding of its relationship with ferroportin (FP) and divalent metal transporter1 in primary iron overload syndromes (PIOSs). In 2012, we proposed a classification of PIOSs based on the Hep25/FP system, which consists of prehepatic aceruloplasminemia, hepatic hemochromatosis (HC), and posthepatic FP disease (FP-D). However, in consideration of accumulated evidence on PIOSs, we aimed to renew the classification. Methods: We reviewed the 2012 classification and retrospectively renewed it according to new information on PIOSs. Results: Iron-loading anemia was included in PIOSs as a prehepatic form because of the newly discovered erythroferrone-induced suppression of Hep25, and the state of traditional FP-D was remodeled as the BIOIRON proposal. The key molecules responsible for prehepatic PIOSs are low transferrin saturation in aceruloplasminemia and increased erythroferrone production by erythroblasts in iron-loading anemia. Hepatic PIOSs comprise four genotypes of HC, in each of which the synthesis of Hep25 is inappropriately reduced in the liver. Hepatic Hep25 synthesis is adequate in posthepatic PIOSs; however, two mutant FP molecules may resist Hep25 differently, resulting in SLC40A1-HC and FP-D, respectively. PIOS phenotypes are diagnosed using laboratory tests, including circulating Hep25, followed by suitable treatments. Direct sequencing of the candidate genes may be outsourced to gene centers when needed. Laboratory kits for the prevalent mutations, such as C282Y, may be the first choice for a genetic analysis of HC in Caucasians. Conclusions: The revised classification may be useful worldwide.

Indexed as

EthnicityFerroportinHemochromatosisHepcidin25Iron overload syndrome

Identifiers

PMID38638373
PMCPMC11022062
OpenAlexW4394729045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.